Puma Biotechnology, Inc.

Healthcare · Biotechnology · United States

Last price 10.54 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 544.08M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breas...